Safety and Immunogenicity of 2 or 3 Doses of MenACWY Conjugate Vaccine in Healthy Infants and the Effects of a Booster Dose of MenACWY Administered in the Second Year of Life

Completed · Phase 3

Conditions studied: Meningococcal Disease, Meningococcal Meningitis

In brief

The purpose of this study was to assess immunogenicity of a 3-dose versus 4-dose infant vaccination schedule including kinetics of immune response in the early phases of the series.

Key facts

Study ID
NCT01214837
Run by
Novartis Vaccines
People needed
751
Starts
2010-10-01
Expected to finish
2012-05-01
Last updated by the study team
2018-10-09

Who can join

Age: 0 and older, up to 0. Sex: any. Healthy volunteers: accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.